Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target from $353 to $399 on September 29. In order to incorporate the latest investor conferences and revised revenue guidance into its model, the firm marginally raised its 2025 forward revenue expectations from $2.627 billion to $2.639 billion.
In addition to adding 100 basis points to the operating margin in 2025 and 2026, Canaccord has increased its 2026 revenue projection for Insulet Corporation from $3.033 billion to $3.046 billion.
Despite the revenue gains, Canaccord modified its net interest expense assumptions and dropped its earnings per share expectation to $5.74 from $6.09 and its 2026 operating income estimate to $549.3 million from $561.0 million.
Insulet Corporation is a global leader in tubeless insulin pump technology, offering innovative diabetes management solutions through its Omnipod Insulin Management System.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
